1-4 of 4
Thomas Rückrich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Imatinib Mesylate and Nilotinib Affect the MHC-Class I Presentation by Modulating the Proteasomal Processing of Antigenic Peptides.

Stefanie Held, Stefan Tenzer, Thomas Rückrich, Karin von Schwarzenberg, Anita Bringmann, Annkristin Heine, Hansjörg Schild, Christoph Driessen, MD, Peter Brossart, MD
Journal: Blood
Blood (2009) 114 (22): 2169.
https://doi.org/10.1182/blood.V114.22.2169.2169
Published: 2009
Journal Articles

Imatinib Inhibits Proteasomal Activity in CML Cells.

Stefanie A.E. Held, Katharina M. Brauer, Thomas Rückrich, Daniela Werth, Karin von Schwarzenberg, Anita Bringmann, Lothar Kanz, Frank Grünebach, Christoph Driessen, Peter Brossart
Journal: Blood
Blood (2007) 110 (11): 4531.
https://doi.org/10.1182/blood.V110.11.4531.4531
Published: 2007
Journal Articles

Acquired Bortezomib (Velcade®)-Resistance Is Accompanied by Downmodulation of Proteasome Activity and Upregulation of Tripeptidyl Peptidase II (TPPII) and a Ubiquitin-Specific Protease.

Christoph Driessen, Jeanette Gogel, Marianne Kraus, Huib Ovaa, Alexander Beck, Thomas Rückrich
Journal: Blood
Blood (2005) 106 (11): 3375.
https://doi.org/10.1182/blood.V106.11.3375.3375
Published: 2005
Journal Articles

Activity Profiling of Proteasome Subunits and Deubiquitinating Enzymes in Human Hematopoetic Malignancies.

Christoph Driessen, Marianne Kraus, Jeanette Gogel, Alexander Beck, Winfried Kammer, Huib Ovaa, Herman Overkleeft, Thomas Rückrich
Journal: Blood
Blood (2005) 106 (11): 617.
https://doi.org/10.1182/blood.V106.11.617.617
Published: 2005